6SWN

N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH iBET-BD1 (GSK778)


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.28 Å
  • R-Value Free: 0.212 
  • R-Value Work: 0.193 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history


Literature

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation.

Gilan, O.Rioja, I.Knezevic, K.Bell, M.J.Yeung, M.M.Harker, N.R.Lam, E.Y.N.Chung, C.W.Bamborough, P.Petretich, M.Urh, M.Atkinson, S.J.Bassil, A.K.Roberts, E.J.Vassiliadis, D.Burr, M.L.Preston, A.G.S.Wellaway, C.Werner, T.Gray, J.R.Michon, A.M.Gobbetti, T.Kumar, V.Soden, P.E.Haynes, A.Vappiani, J.Tough, D.F.Taylor, S.Dawson, S.J.Bantscheff, M.Lindon, M.Drewes, G.Demont, E.H.Daniels, D.L.Grandi, P.Prinjha, R.K.Dawson, M.A.

(2020) Science 368: 387-394

  • DOI: 10.1126/science.aaz8455
  • Primary Citation of Related Structures:  
    6SWO, 6SWN, 6SWQ, 6SWP

  • PubMed Abstract: 
  • The two tandem bromodomains of the BET proteins enable chromatin binding to facilitate transcription. Drugs that inhibit both bromodomains equally have shown efficacy in certain malignant and inflammatory conditions. To explore the individual functio ...

    The two tandem bromodomains of the BET proteins enable chromatin binding to facilitate transcription. Drugs that inhibit both bromodomains equally have shown efficacy in certain malignant and inflammatory conditions. To explore the individual functional contributions of the first (BD1) and second (BD2) bromodomains in biology and therapy, we developed selective BD1 and BD2 inhibitors. We found that steady-state gene expression primarily requires BD1 whereas the rapid increase of gene expression induced by inflammatory stimuli requires both BD1 and BD2 of all BET proteins. BD1 inhibitors phenocopied the effects of pan-BET inhibitors in cancer models whereas BD2 inhibitors were predominantly effective in models of inflammatory and autoimmune disease. These insights into the differential requirement of BD1 and BD2 for the maintenance and induction of gene expression may guide future BET targeted therapies.


    Organizational Affiliation

    Centre for Cancer Research, University of Melbourne, Melbourne, VIC, Australia.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Bromodomain-containing protein 4AAA127Homo sapiensMutation(s): 0 
Gene Names: BRD4HUNK1
Find proteins for O60885 (Homo sapiens)
Explore O60885 
Go to UniProtKB:  O60885
NIH Common Fund Data Resources
PHAROS  O60885
Protein Feature View
Expand
 ( Mouse scroll to zoom / Hold left click to move )
  • Reference Sequence
Small Molecules
Ligands 3 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
LWB
Query on LWB

Download CCD File 
AAA
4-[2-(methoxymethyl)-1-[(1~{R})-1-phenylethyl]-8-[[(3~{S})-pyrrolidin-3-yl]methoxy]imidazo[4,5-c]quinolin-7-yl]-3,5-dimethyl-1,2-oxazole
C30 H33 N5 O3
ZORLJXWXFABTPZ-CTNGQTDRSA-N
 Ligand Interaction
GLU
Query on GLU

Download CCD File 
AAA
GLUTAMIC ACID
C5 H9 N O4
WHUUTDBJXJRKMK-VKHMYHEASA-N
 Ligand Interaction
EDO
Query on EDO

Download CCD File 
AAA
1,2-ETHANEDIOL
C2 H6 O2
LYCAIKOWRPUZTN-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.28 Å
  • R-Value Free: 0.212 
  • R-Value Work: 0.193 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 38.28α = 90
b = 42.32β = 90
c = 90.82γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
XDSdata reduction
Aimlessdata scaling

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

  • Deposited Date: 2019-09-22 
  • Released Date: 2020-04-01 
  • Deposition Author(s): Chung, C.

Revision History 

  • Version 1.0: 2020-04-01
    Type: Initial release
  • Version 1.1: 2020-05-06
    Changes: Database references